Abstract
The interaction of calreticulin with amyloid beta (Aβ) was investigated using solid phase and solution binding assays. Calreticulin bound Aβ 1-42 in a time and concentration dependent fashion. The binding was optimal at pH 5 and was stimulated by Ca2+ and inhibited by Zn2+ at pH 7. Interaction took place through the hydrophobic C-terminus of Aβ 1- 42 and the polypeptide binding site of calreticulin. The results are discussed in the light of a reported role of calreticulin as a cell surface scavenger receptor.
Keywords: Calreticulin, chaperone, amyloid beta, Alzheimer disease
Protein & Peptide Letters
Title: Interaction of Calreticulin with Amyloid Beta Peptide 1-42
Volume: 15 Issue: 1
Author(s): G. Houen, K. Duus and P. R. Hansen
Affiliation:
Keywords: Calreticulin, chaperone, amyloid beta, Alzheimer disease
Abstract: The interaction of calreticulin with amyloid beta (Aβ) was investigated using solid phase and solution binding assays. Calreticulin bound Aβ 1-42 in a time and concentration dependent fashion. The binding was optimal at pH 5 and was stimulated by Ca2+ and inhibited by Zn2+ at pH 7. Interaction took place through the hydrophobic C-terminus of Aβ 1- 42 and the polypeptide binding site of calreticulin. The results are discussed in the light of a reported role of calreticulin as a cell surface scavenger receptor.
Export Options
About this article
Cite this article as:
Houen G., Duus K. and Hansen R. P., Interaction of Calreticulin with Amyloid Beta Peptide 1-42, Protein & Peptide Letters 2008; 15 (1) . https://dx.doi.org/10.2174/092986608783330459
DOI https://dx.doi.org/10.2174/092986608783330459 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy
Current Pharmaceutical Design Innate Immunity and Primary Biliary Cirrhosis
Current Molecular Medicine Editorial [Hot topic:Pharmacological Brain Imaging in the Healthy and Sick Brain (Executive Editor: F.M. Van Der Veen)]
Current Pharmaceutical Design IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) Catechol-O-Methyltransferase and Alzheimer's Disease: A Review of Biological and Genetic Findings
CNS & Neurological Disorders - Drug Targets Preclinical Hepatoprotective Effect of Herbalism Against Ethanol Induced Hepatotoxicity: A Review
Current Drug Metabolism Acetylcholinesterase Inhibitors as Pretreatment Before Acute Exposure to Organophosphates: Assessment Using Methyl-Paraoxon
CNS & Neurological Disorders - Drug Targets Physiological Basis for Contractile Dysfunction in Heart Failure
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Alzheimer Research Advances in Whole Genome Sequencing Technology
Current Pharmaceutical Biotechnology Polypharmacology Approach Against Migraine with Aura and Brain Edema for the Development of an Efficient Inhibitor and its Analogues
Current Computer-Aided Drug Design Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Comparative Pharmacokinetic Evaluation of Controlled Release Matrix Tablet of Milnacipran Hydrochloride in Rabbit
Drug Delivery Letters Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Aptamers as Innovative Diagnostic and Therapeutic Agents in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Ligand Based Validated Comparative Chemometric Modeling and Pharmacophore Mapping of Aurone Derivatives as Antimalarial Agents
Current Computer-Aided Drug Design The Design and Development of Fesoterodine as a Prodrug of 5- Hydroxymethyl Tolterodine (5-HMT), the Active Metabolite of Tolterodine
Current Medicinal Chemistry Blood-brain Barrier Disruption May Contribute to White Matter Lesions in the Setting of Internal Jugular Venous Stenosis
Current Neurovascular Research Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence
Current Neuropharmacology